In a single-arm phase II study from the German-Austrian AML Study Group (AMLSG), adults up to 70 years of age with newly diagnosed FLT3-ITD-mutated AML received intensive chemotherapy plus midostaurin, followed by allogeneic HSCT and 1 year of midostaurin maintenance [39]. Here, FLT3 is linked to acute myeloid leukemia.